Table 1 Characteristics of prospective comparative controlled trials comparing SLT with topical medication
Author(year) | Design, location | NO. of eyes (SLT/med) | Follow-up | Mean age | Baseline IOP | BCVA C/D | Diagnosis | Definition of success | Degrees of SLT/ Average energy | Medication |
|---|---|---|---|---|---|---|---|---|---|---|
Lai(2004) | SC,RCT, China | 29/29 | 60 m | 51.9 | 26.8 ± 5.6 /26.2 ± 4.2 | 0.1-1.0/ 0.2-1.0 | POAG, OHT | IOP ≤ 21 mmHg | 360 | Topical beta-blocker, pilocarpine, dorzolamide latanoprost as monotherapy or in combination |
0.4 ± 0.2/ 0.5 ± 0.2 | 1.0 ± 0.1 mJ | |||||||||
Nagar(2005) | MC,RCT, UK | 128/39 | 12 m | 63 | 29.3/29 | NA | POAG, OHT, PDS, PEX | IOPR% ≥ 20 % | 360/180/90 | Latanoprost 0.005 % |
0.2-1.7 mJ | ||||||||||
McIlraith(2006) | MC,Pro, Canada | 74/26 | 12 m | 62 | 26/24.6 | NA | POAG, OHT, PDS, PEX | OP ≤ 22 mmHg | 180 | Latanoprost 0.005 % |
0.5 ± 0.2/ 0.6 ± 0.2 | 0.8 mJ | |||||||||
Nagar(2009) | SC,RCT, UK | 20/20 | 4-6 m | NR | 26.1 ± 4.0 /22.8 ± 4.5 | NA | POAG, OHT | IOPR% ≥ 20 % | 360 | Latanoprost 0.005 % |
0.2-1.4 mJ | ||||||||||
Katz(2012) | MC,RCT, USA | 67/60 | 9-12 m | NR | 25.0 ± 2.2 /24.5 ± 2.2 | NA | POAG, PEX, OHT | Arrived target IOP | 360 followed by 180 0.2-1.2 mJ | Topical prostaglandin analog, β-blocker, brimonidine, carbonic anhydrase inhibitor, in combination |